Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.

ABSTRACT:

Purpose

To show that the immunomodulatory drug lenalidomide can be used in patients with relapsed multiple myeloma to augment vaccine responses.

Experimental design

Early phase clinical trial of patients with multiple myeloma who received at least one prior therapy. Patients were treated with single-agent lenalidomide and randomized to receive two vaccinations with pneumococcal 7-valent conjugate vaccine (PCV) on different schedules. Cohort A received the first PCV vaccination prior to the initiation of lenalidomide and the second vaccination while on lenalidomide. Cohort B received both vaccinations while on lenalidomide.

Results

PCV-specific humoral and cellular responses were greater in cohort B than A and were more pronounced in the bone marrow than the blood, sug

SUBMITTER: Noonan K 

PROVIDER: S-EPMC3640365 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature